Coagulopathy in a Patient with X-Linked Hyper-IgM Syndrome Who Developed Kaposi's Sarcoma [2]

American Journal of Hematology

Volumn 75, Issue 2, 2004, Pages 116-117

  Nagasawa, Masayuki ^a   Itoh, Sukeyuki ^a   Sawada, Yasuyuki ^a   Morio, Tomohiro ^a   Nonoyama, Shigeaki ^a   Mizutani, Shuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD40 ANTIGEN; CD40 LIGAND; CYCLOPHOSPHAMIDE; D DIMER; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; FRESH FROZEN PLASMA; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; BLOOD CELL COUNT; BRONCHIECTASIS; CASE REPORT; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERIMMUNOGLOBULINEMIA M; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFLAMMATION; KAPOSI SARCOMA; LETTER; MALE; PARTIAL THROMBOPLASTIN TIME; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTHROMBIN TIME; SKIN BIOPSY; STEM CELL TRANSPLANTATION; TH1 CELL; X CHROMOSOME LINKED DISORDER;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHROMOSOMES, HUMAN, X; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOGLOBULIN M; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; SARCOMA, KAPOSI; TREATMENT OUTCOME;

EID: 0742287900     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10460     Document Type: Letter

References (5)

1. Aruffo A, Farrington M, Hollenbaugh D, et al. The CD40 ligand, gp39, is defective in activated T-cells from patients with X-linked hyper-IgM syndrome. Cell 1993;72:291-300.
2. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997:94:1931-1936.
3. Biancone L, Cantaluppi V, Boccellino M, et al. Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma. J Immunol 1999;163:6201-6208.
4. Andre P, Prasad S, Denis CV, et al. CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism. Nat Med 2002;8:247-252.
5. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000;6:114.